Stantum lands $13M for multi-touch touchscreens
French touchscreen maker Stantum Technologies announced that it just brought in $13 million in a second round of funding to expand its sales operations in the U.S., Europe and Asia and advance research on next-generation multi-touch products. Formerly called JazzMutant, Stantum says it was the first to produce a screen that could sense an unlimited number of touchpoints. It brings in revenue by licensing its screen technology to third-party product developers.
Just last month, Stantum struck… Continue Reading
Crocus snags $15.8M to develop magnetic memory chips
French semiconductor maker Crocus Technology has raised $15.8 million in second round financing, in addition to $4.1 million from OSEO, France’s public agency for funding innovation.
The company plans to use the round for continued development of its magnetic random access memory (MRAM) chips, which can store information using magnetic fields. These chips are less volatile, suck less power and are generally faster than the flash memory used in most computers and handheld electronics.
Crocus expects that… Continue Reading
Xytis gets $7.5M to work on central nervous system disorders
Xytis, a privately-held biotech company based in both the U.S. (Irvine, CA) and Europe (London, England and Nyon, Switzerland) has raised a new round of series B funding. The company specializes in making treatments for patients with central nervous system (CNS) disorders.
The $7.5 million round was participated in by the Waltham, MA-based Atlas Venture Funds, the San Mateo, CA-based Sanderling Venture Partners and the Paris, France-based CDC Innovation.
The company previously raised a large $24.5 million… Continue Reading
Life-science briefing: Friday, April 11, 2008
TODAY’S HEADLINES:
Stent maker IDev Tech raises $25M (VentureWire)
Xytis gets $15M for brain-injury drugs (VentureWire)
Diagnostic maker Iris Biotech plans to go public, launch breast-cancer test (Edgar)
RiverVest Venture Partners raises $75M life-science fund (release)
Concentric Medical names Maria Sainz CEO (release)
[Note: I’m a little sad to announce that this will be my last life-science briefing at VentureBeat, although with luck, it won’t be the end of my time here. Starting Monday, I’ll be blogging regularly on the drug industry and… Continue Reading
Life-science briefing: Thursday, March 6, 2008
TODAY’S HEADLINES:
France’s TxCell raises €11M for cell therapy (release)
Healthcare IT firm TriHealix takes in $7M (release)
Healthcare-software provider Anodyne Health acquires Piedmont Healthcare (release)
CEO, CFO resign at inhaled-drug biotech Topigen (release)
France’s TxCell raises €11M for cell therapy – TxCell, a French cell-therapy biotech, raised €10.5 million ($16 million) in a second funding round. Investors included Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure.
The biotech is developing a patient-specific cell therapy for the gastrointestinal autoimmune… Continue Reading